McKinsey January 9, 2025
Anton Mihic, Gaurav Agrawal, Chaitanya Adabala Viswa, Hann Yew, Kevin Webster

Three lighthouse use cases serve as a blueprint for AI’s potential to improve the speed, efficiency, and quality of clinical trials.

Despite dedicated efforts across the biopharmaceutical industry to streamline clinical development, clinical trials remain complex, costly, and time-consuming. These challenges are compounded by an increasingly competitive and crowded trial landscape. Yet accelerating clinical development remains crucial—not just for patients but for the enterprise. A 12-month reduction in the clinical development timeline can add more than $400 million in net present value (NPV) across a sponsor’s portfolio while delivering immeasurable benefits to patients and their families.

Leading biopharma companies are addressing this challenge by adopting AI and machine learning (ML) to accelerate trials through scientific and operational improvements. Our analysis...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Clinical Trials, Technology, Trends
Clinical trial unearths hidden hypertension with automated searches of health records
Key Considerations for Foreign Clinical Trials When Looking Abroad for Product Development
WHO releases Lancet papers that delve further into clinical trial guidance
First clinical trial of an AI therapy chatbot yields significant mental health benefits
AI could help sonographers identify abnormalities in unborn babies more quickly

Share This Article